Mouse IgM Isotype Control – Purified in vivo PLATINUM™ Functional Grade

Common in vivo applications of the Nan mouse (neonatal anemia, "Nan") clone in mice include studies on hematopoiesis, erythropoiesis, and genetic regulation of blood cell development. The Nan mouse carries a spontaneous point mutation (E339D) in the transcription factor Klf1 (Erythroid Krüppel-Like Factor, EKLF), which leads to anemia and defects in erythroid development.

Key in vivo applications:

• Modeling hereditary anemia: The Nan mouse is widely used to study the molecular mechanisms underlying congenital, neonatal, or hereditary anemia, since the mutant Klf1 protein disrupts normal erythropoiesis.
• Developmental hematology: Researchers use Nan mice to investigate how mutations in Klf1 affect erythroid precursor cell differentiation and maturation in vivo, as well as to study compensatory mechanisms during mouse embryonic and neonatal development.
• Gene regulation studies: The model provides insight into Klf1’s broader roles in transcriptional control of erythroid-specific genes, supporting functional genetic and epigenetic studies in a living animal.
• Testing therapeutic interventions: Due to their reproducible anemia phenotype, Nan mice are used to test potential therapies (e.g., gene editing, pharmaceuticals) targeting erythroid defects or attempting to correct Klf1-related errors in vivo.

Summary Table: Nan Mouse Clone In Vivo Applications

The Nan mouse model is considered a functional in vivo system for unraveling causes and potential treatments for red blood cell disorders with clear translational relevance to human hematology.

If you are referring to "nanocarrier" imaging or "nano" technology (as alternate meanings), in vivo applications include drug delivery, gene editing, and biodistribution studies, as discussed in several recent mouse studies using LNPs and nanocarriers. Let me know if you intended one of these alternative meanings.

Antibodies and proteins are extensively used in conjunction with nanotechnology across various applications in research and medicine. The integration of these biological molecules with nanostructures has opened up diverse possibilities for diagnostics, therapeutics, and controlled assembly systems.

Nanobodies (Nbs)

Nanobodies represent one of the most prominent protein scaffolds used with nanotechnology. These single-domain antibody fragments are derived from heavy-chain-only IgG antibodies found in the Camelidae family and cartilaginous fish. Nanobodies offer several advantages for nanotechnology applications, including their stability, diverse binding capabilities, absence of cross-reactive Fc regions, easy multivalency, and compatibility with gold nanoparticles.

In diagnostic applications, nanobodies have been successfully implemented in Lateral Flow Immunoassays (LFIA) and ELISA platforms. For example, nanobody clones P158 and P86 conjugated to labeled beads have been used to detect SARS-CoV-2 spike proteins across multiple variants. Additionally, nanobody-based sandwich ELISAs have been developed to quantify protein toxins TcdA and TcdB of Clostridioides difficile, and serum ferritin-specific nanobodies have achieved detection limits as low as 1.01 ng/mL.

Antibody-Conjugated Nanoparticles

Antibody-conjugated nanoparticles (ACNPs) are widely used for targeted drug delivery to cancer cells. These systems leverage the specificity of antibodies to direct therapeutic payloads precisely to diseased tissues while minimizing off-target effects. The technology has advanced to include sophisticated antibody capture systems that attach antibodies to the surface of lipid nanoparticles (LNPs) in their optimal orientation, enabling specific in vivo delivery.

Therapeutic Applications

In anti-parasitic therapy, nanobodies have been conjugated with various carriers and drugs. Researchers have created nanobodies against trypanosome variant surface glycoprotein (VSG) conjugated to poly(lactic-co-glycolic acid) or chitosan carriers loaded with pentamidine, reducing the required curative dose multiple-fold. Chimeric constructs combining anti-trypanosome nanobodies with truncated versions of human trypanolytic protein APOL1 have demonstrated potent anti-parasite effects in vivo.

For toxin neutralization, nanobodies have been developed in various formats including bispecific nanobodies for scorpion toxins, nanobody-human Fc conjugates, and humanized nanobodies. Similar applications extend to snake envenoming, with nanobody-Fc conjugates developed against α-Cobratoxin of the Naja kaouthia snake.

DNA Nanostructure Assembly

Endogenous human antibodies themselves can function as molecular builders for DNA nanotechnology. Researchers have engineered DNA bricks with antigen recognition tags that assemble into tubular nanostructures only in the presence of specific antibodies. These structures can be both assembled and dismantled by different antibody workers, creating highly intelligent and controllable DNA nanostructures.

Immunomodulatory Applications

In immunology, nanoparticles are combined with various immunomodulatory proteins including cytokines such as GM-CSF, IL-12, IL-15, and FMS-related tyrosine kinase 3 ligand (FLT3L) to enhance cytotoxic T lymphocyte (CTL) responses. Co-stimulatory ligands like CD40 ligand (CD40L) and glucocorticoid-induced TNFR-related protein (GITR) are multimerized with nanoparticles to control lymphocyte activation with greater precision.

The key scientific findings associated with "clone nan" citations primarily involve studies of the novel sodium channel gene NaN and its unique characteristics in neuroscience research. There may be ambiguity in the query: if you meant "citations of cloned NaN sodium channels," the summary below applies; however, if you intended a different context—such as "clone nan" as a generic term or software tool—please clarify.

Key findings from NaN sodium channel cloning and citations:

• NaN is a novel voltage-gated sodium channel alpha subunit distinct from all previously identified rat Na channels, with only about 47–55% amino acid identity to the closest subtypes.
• NaN is predicted to be tetrodotoxin-resistant (TTX-R) and is preferentially expressed in sensory neurons, suggesting a specialized physiological role.
• Structural analysis revealed NaN shares features with both major sodium channel subfamilies, hinting at either an ancestral relationship or that NaN forms a third subfamily, with properties intermediate between the two.
• Functionally, NaN has distinctive regions:
  • Its inactivation tripeptide (IFM) is more like subfamily 1, yet other motifs are characteristic of subfamily 2.
  • The longer linker between certain domains (S3–S4 of D4) may contribute to faster recovery from inactivation, a trait verified in other channels by mutagenesis studies.
  • Key amino acid substitutions confer its TTX-R phenotype, supporting its identity as a novel functional channel.

Contextual findings and scientific relevance:

• The cloning and characterization of NaN have broadened understanding of sodium channel diversity, sensory neuron physiology, and evolutionary relationships among channel subfamilies.

If you intended findings related to nanoparticles (NANPs) or another "nan" clone entity in literature, please clarify, as search results for nucleic acid nanoparticles and nanomaterials are unrelated to the cloned sodium channel gene findings.

Dosing regimens of antibody clones vary significantly across mouse models due to differences in clone target, mouse strain, disease context, and desired immunological effect. There is no universal dosing regimen; dosing must be optimized empirically for each experimental setup, often relying on established ranges and schedules reported in published studies or technical guides.

Key factors influencing dosing variation:

• Mouse strain and model type: Different strains and disease models (e.g., cancer, infection, autoimmunity) may require adjustment in dose to account for immunological responsiveness or baseline health differences.
• Clone identity and target: Each clone (e.g., RMP1-14, 10F.9G2, 9H10) has a recommended dose range and schedule reflecting its mechanism of action and pharmacodynamics.

Examples of dosing regimens for common clones:

• RMP1-14 (Anti-PD-1): 200–500 μg per mouse, injected intraperitoneally every 3–4 days; commonly used at 200 μg in tumor models like MC38 and B16.
• 10F.9G2 (Anti-PD-L1): 100–250 μg per mouse, intraperitoneally 2–3 times per week; used in both cancer and infection settings.
• 29F.1A12 (Anti-PD-1): 100–200 μg per mouse (~5 mg/kg), three doses at 3-day intervals.
• 9H10 (Anti-CTLA-4): 100–200 μg per mouse, every ~3 days; often in combination regimens.
• GK1.5 (Anti-CD4): 200–250 μg per mouse, 2–3 times per week, used for T-cell depletion in autoimmunity, infection, tumor rejection, and transplant studies.
• 2.43 (Anti-CD8): 250 μg per mouse, 2–3 times per week for cytotoxic T-cell depletion.

For other antibody clones (e.g., H22, anti-IFNγ):

• No standard dose or schedule is universally adopted—optimal dose is determined empirically by reviewing literature, pilot titrations, and desired experimental outcomes. Researchers select the dosing schedule based on parameters such as efficacy, toxicity, antibody pharmacokinetics, and the specific immunological endpoint under investigation.

Additional considerations:

• Route of administration is most commonly intraperitoneal, but can vary to intratumoral or intravenous depending on experimental goals.
• Desired immunological effect (agonism, antagonism, depletion) may require modification of dose or treatment schedule for optimal results.

When planning antibody clone dosing in mice, researchers should refer to published data relevant to their disease model and mouse strain, start with manufacturer or literature suggested ranges, and perform in vivo titration as needed.